The blood-brain barrier (BBB) lumen is coated by a carbohydrate-rich meshwork known as the brain endothelial glycocalyx layer. Stanford researchers have shown that the brain endothelial glycocalyx is highly dysregulated during aging and neurodegenerative disease. They furthermore identified that a class of glycans known as mucins are highly downregulated on the brain endothelium during aging and in neurodegenerative diseases, which in turn leads to increased BBB leakiness and brain bleeds. Finally, they show brain-endothelial specific viruses (AAVs) can be therapeutically used to overexpress the mucin biosynthetic genes and restore BBB function (less leakiness) and decrease neuroinflammation.
Stage of Development
In vivo: mouse models
- Neurodegenerative diseases: Alzheimer's, Parkinson's, multiple sclerosis, ALS, traumatic brain injury (TBI), stroke, etc.
- Novel way of treating blood brain barrier dysfunction and inflammation
Chemically modified AAVsS21-280
Chemically modified AAVs
First in class covalent inhibitor of Fis1 prevents mitochondrial fragmentation and dysfunctionS23-492
First in class covalent inhibitor of Fis1 prevents mitochondrial fragmentation and dysfunction
Exosomes from Postpartum Nursing Females as Therapy for Ischemic InjuryS22-069
Exosomes from Postpartum Nursing Females as Therapy for Ischemic Injury